Pancreatic Cancer Research

ResearcherCenter For Biomarker Research In MedicineActive in the last 2 years

Armin Gerger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3888-5401; OpenAlex author ID A5047374036. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2013: 4 papers · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 18

  1. Chemotherapy sequence in advanced pancreatic cancer – still a matter of debate? Co-author DOI 10.21203/rs.3.rs-4461811/v1↗
  2. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Co-author DOI 10.1055/a-1548-4847↗
  3. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non… Co-author DOI 10.1016/j.ejca.2020.11.003↗
  4. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Last author DOI 10.1016/j.ejca.2021.03.040↗
  5. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Co-author DOI 10.1002/cam4.3233↗
  6. The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc anal… Last author DOI 10.1177/1758835919900872↗
  7. Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12051154↗
  8. The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers12071798↗
  9. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer. Co-author DOI 10.1515/cclm-2018-0016↗
  10. Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis. Co-author DOI 10.1007/s00508-018-1383-3↗
  11. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. First author DOI 10.1136/jclinpath-2014-202451↗
  12. The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. Co-author DOI 10.1515/cclm-2014-0447↗
  13. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Co-author DOI 10.1038/bjc.2013.701↗
  14. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0104730↗
  15. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. First author DOI 10.1038/bjc.2013.332↗
  16. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer First author DOI 10.1038/bjc.2013.591↗
  17. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. Co-author DOI 10.1136/jclinpath-2012-201394↗
  18. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0078225↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Stotz · 15 shared papers, 2013–2022 · strength 0.99
  2. Martin Pichler Pichler · 15 shared papers, 2013–2022 · strength 0.99
  3. Jakob Michael Riedl · 7 shared papers, 2020–2024 · strength 0.82
  4. Konstantin Schlick · 7 shared papers, 2018–2024 · strength 0.79
  5. Peter Kornprat · 13 shared papers, 2013–2020 · strength 0.76
  6. Joanna Szkandera · 11 shared papers, 2013–2020 · strength 0.56
  7. Dominik Andreas Barth · 5 shared papers, 2020–2022 · strength 0.53
  8. Richard Greil · 4 shared papers, 2020–2024 · strength 0.52
  9. Eva Valentina Klocker · 4 shared papers, 2019–2020 · strength 0.39
  10. Florian Moik · 2 shared papers, 2021–2022 · strength 0.23
  11. Gerald Höefler · 6 shared papers, 2013–2015 · strength 0.21
  12. Lukas Weiß · 1 shared paper, 2024 · strength 0.21
  13. Wolfgang Eisterer · 2 shared papers, 2020–2021 · strength 0.18
  14. Gerald W. Prager · 2 shared papers, 2020–2021 · strength 0.18
  15. Eva Asamer · 2 shared papers, 2018–2020 · strength 0.17
  16. Anna Lena Lembeck · 2 shared papers, 2018–2019 · strength 0.16
  17. Cihan Ay · 1 shared paper, 2022 · strength 0.12
  18. D. Reitz · 2 shared papers, 2014–2015 · strength 0.09
  19. Wael Al Zoughbi · 2 shared papers, 2013 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.